National Critical-Medicines Tender Recovery Leader

The mandate

Three manufacturers that won national framework volume have missed deliveries or invoked supply constraints across injectable anti-infectives, anaesthetics and other critical medicines. Agency reporting still counts maximum awarded quantity, even where production slots, batches, release, language packs, wholesaler stock or lawful call-off capacity are absent. Hospitals submit precautionary demand that compounds the distortion. The director-general needs one temporary executive to recover executable tender supply while maintaining equal treatment, auditability and the boundary between procurement evidence and clinical prioritisation.

The leader begins within fourteen days for twelve months. The first fifteen working days will reconcile all 46 medicines by awarded source, committed production, batch and release state, pack, inventory ownership, delivery point, demand and legal remedy. By day 45, each national exposure must have a lawful primary, alternate, emergency or conservation decision path. Four tender-call-off cycles, two shortage seasons and one simultaneous supplier-failure exercise precede a five-week handover.

Exit requires awarded and usable quantity to reconcile; call-offs to reflect evidenced capacity and framework rights; hospital demand to separate consumption, backlog and precaution; supplier recovery to include batch and release gates; and public reporting to explain uncertainty without disclosing protected terms. The permanent leader receives product-source dossiers, contract interpretations from counsel, call-off histories, inventory and demand views, open remedies, shortage decisions, performance evidence and six months of forward exposures, then chairs two cycles unaided.

Within delegated public-procurement rules, the interim may sequence call-offs, activate already-approved framework alternates, reserve agency-owned released stock, commission authorised logistics and approve continuity spend up to EUR 75 million. Procurement officials execute awards and material contract changes; counsel interprets law and remedies; regulators and Quality functions control product status; clinicians set treatment guidance; hospitals manage individual patients; ministers and the council approve extraordinary purchasing or allocation policy.

New tender-law design, litigation conduct, medicine authorisation, batch release, clinical conservation protocols, individual hospital allocation, reimbursement and permanent industrial policy sit outside scope. The leader cannot create capacity by treating a framework ceiling, unconfirmed production slot or unreleased batch as supply. Every national quantity must carry source, contract route, production and quality state, pack, owner, destination, realistic availability and the authorised decision still required.

Why this seat is open

The agency’s procurement director remains in post but cannot independently command a recovery involving disputed supplier performance, national inventory and hospital demand while administering the affected contracts. The temporary seat creates accountable continuity authority without prejudging legal remedies. It requires a leader who has recovered public medicine supply transparently under scrutiny and can hand control back after framework discipline is restored.

What you will own

• Reconcile 46 medicine positions across award, call-off, production, batch, release, pack, ownership, logistics and hospital demand.
• Remove unsupported framework ceilings and duplicate reservations from national cover while preserving an auditable baseline.
• Run lawful primary, alternate and emergency call-off decisions using evidenced capacity, lead time, clinical policy and regional consequence.
• Challenge supplier recovery below account-management dates through materials, line slots, campaigns, testing, release and pack availability.
• Segment hospital demand into consumption, scheduled need, backlog, precaution and transfer so amplification remains visible.
• Exercise simultaneous default by two framework winners and test counsel, regulator, hospital, ministerial and public-reporting interfaces.
• Induct the permanent leader through live call-offs with dossiers, demand evidence, remedies, decisions and forward exposures.

Candidate qualifications

• Held executive public-medicine procurement, national pharmaceutical supply or critical-product continuity authority under formal tender rules.
• Has recovered essential or critical medicines after awarded manufacturers defaulted without compromising equal treatment or auditability.
• Understands framework ceilings, call-offs, production capacity, batch release, pack configuration, wholesaler stock and hospital demand.
• Can exercise delegated continuity authority while preserving counsel, Procurement, regulator, Quality, clinician and ministerial decisions.
• Has separated genuine hospital demand from precautionary amplification and communicated shortage uncertainty under public scrutiny.
• Completed a national recovery with defensible records, trained permanent leadership and supplier performance evidence fit for remedies.

Non-negotiables

• Can begin in Paris within fourteen days and sustain manufacturer, wholesaler, hospital and regional-store travel.
• Brings direct public tender and critical-medicine supply depth; company allocation or commercial account management alone is insufficient.
• Will disclose manufacturer, wholesaler, hospital, logistics, legal-adviser and government relationships before appointment.
• Accepts no tender-law, award, contract-variation, litigation, regulatory, Quality, clinical, patient or ministerial authority.

1. 49 words maximum. Describe framework volume you removed from national cover after the awarded supplier’s evidence failed.
2. 49 words maximum. How did you prevent precautionary hospital orders from amplifying a genuine medicine shortage?
3. 49 words maximum. What manufacturer, wholesaler, hospital or public-body relationship could impair your independence?

---